Clinical Trials Logo

Filter by:
NCT ID: NCT03306160 Not yet recruiting - Clinical trials for End Stage Renal Disease

Prognostic Value of Central and BracHial Ambulatory Blood Pressure Monitoring in ERSD Patients Treated With HeMOdialysis

C-HEMO
Start date: October 10, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This is a prospective cohort study which aims to explore the significance of brachial and central ambulatory blood pressure monitoring in predicting cardiovascular risk in patients with end stage renal disease who are treated with hemodialysis. Enrolled patients will receive a 48-hour central and brachial ambulatory blood pressure monitoring at its first-time dialysis after enrollment. And their cardiovascular events and deaths at first and third year will be followed-up.

NCT ID: NCT03306121 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

TPF+CCRT vs.CCRT+PF in Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: October 20, 2017
Phase: Phase 3
Study type: Interventional

To see the effect of induction chemotherapy(TPF) followed by chemoradiotherapy VS concurrent chemoradiotherapy collowed by adjuvant chemotherapy (PF) inin treating with locoregionally advanced nasopharyngeal carcinoma (NPC).

NCT ID: NCT03306030 Recruiting - Health Behavior Clinical Trials

Comparison of Two Methods for Bowel Preparation in Patients With Constipation

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Constipation is a common high risk factor for inadequate bowel preparation. The bowel cleansing efficacy of the standard split-does of 4L seems to be suboptimal in constipated patients. We hypothesized that compared with the standard preparation regime, the split-dose with three times of 4L PEG may be superior in BP quality.

NCT ID: NCT03305887 Recruiting - Wound Closure Clinical Trials

Symmetric on Total Knee Arthoplasty (TKA)

SFX
Start date: June 12, 2017
Phase: N/A
Study type: Interventional

A post-marketing prospective, multicenter, randomized controlled study to evaluate the wound closure efficiency of STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device (STRATAFIX Symmetric PDS Plus) compared to conventional sutures in total knee arthoplasty (TKA)

NCT ID: NCT03304288 Recruiting - Clinical trials for Immune Thrombocytopenia

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Start date: January 1, 2017
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and ATRA in patients with steroid-resistant/relapsed ITP.

NCT ID: NCT03304041 Recruiting - Clinical trials for Irritable Bowel Syndrome

Efficacy of Low-FODMAPs Dietary Therapy for Irritable Bowel Syndrome in China

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The primary aim of our study is to carry out a randomized trial to evaluate the efficacy of low-FODMAPs dietary therapy compared to conventional therapy for IBS patients recruited from tertiary hospitals in China. Secondary aims of this research include an analysis of clinical, physiological and microbiological factors that may predict IBS patient response to this dietary intervention.

NCT ID: NCT03303495 Recruiting - Clinical trials for Colorectal Neoplasms

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Start date: November 14, 2011
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the non-inferiority of overall survival FOLFIRI with or without Bevacizumab compared with Irinotecan (CPT-11) with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.

NCT ID: NCT03303378 Recruiting - Clinical trials for Reperfusion Injury, Myocardial

Effects of Melatonin on Reperfusion Injury

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

Acute myocardial infarction is a major cause of mortality and morbidity. Primary percutaneous coronary intervention (pPCI) is currently the most effective treatment strategy in acute myocardial infarction. However, a sizable number of patients fail to restore optimal myocardial reperfusion, mostly because of the 'no-reflow' phenomenon. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Several studies have shown that melatonin protects against ischemia/reperfusion injury (IRI). In our previous study, melatonin markedly reduced infarcted area, improved cardiac function and reduced lactate dehydrogenase release in rats. The investigators planned to research the cardioprotective effects of intravenous melatonin administered prior to reperfusion and continued after restoration of coronary blood flow in patients with ST segment elevation myocardial infarction undergoing pPCI.

NCT ID: NCT03302455 Not yet recruiting - Insomnia Clinical Trials

E-aid Cognitive Behavior Therapy for Insomnia to Prevent Transition From Short-term to Chronic Insomnia in China

Start date: October 2017
Phase: N/A
Study type: Interventional

Short-term insomnia is one of the most common sleep disorders. Online cognitive behavioral therapy for insomnia (e-aid Cognitive Behavioral Therapy for Insomnia, eCBTI) has received wide attention in recent years. Foreign countries already have some eCBTI treatment tool, shown similar efficacy as standard CBTI, but how eCBTI can help in short-term insomnia disorders require further exploration and examination. In this study, Investigators will establish eCBTI treatment tool to test whether eCBTI can reduce the conversion of short-term insomnia disorder to chronic insomnia disorder; and whether they can reduce short-term insomnia, anxiety, depression and improve quality of life

NCT ID: NCT03302403 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Start date: October 2017
Phase: N/A
Study type: Interventional

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets. CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens. The investigational CAR T cells and proposed indications are as follows: CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.